Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2015-07-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 151.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including cash flows from operating, investing, and financing activities, reconciliation of cash, and payments to directors. It references a specific quarter ended 30th June 2015 and includes substantive financial statements and analysis. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. The Appendix 4C is a recognized quarterly report format used in Australian Securities Exchange (ASX) filings for quarterly cash flow reporting. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q4 2015
2015-07-29 English
Change of Share Registry 1 page 77.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Imugene Limited regarding a change in their share registry service provider. It does not contain financial data, management discussion, voting results, or any detailed report content. The document is under 5,000 characters and serves as a notification of a corporate administrative change. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2015-07-23 English
New Research Note available from Edison Investment Research 1
Report Publication Announcement Classification · 95% confidence The document is an ASX release dated 13 July 2015 from Imugene Limited announcing the publication of a new research note by Edison Investment Research. The text provides a link to view the research note but does not contain the research note itself or any substantive financial data. The document is short (1026 characters) and serves as an announcement of the availability of a report rather than the report itself. According to the 'Menu vs Meal' rule, such announcements should be classified as Report Publication Announcement (RPA).
2015-07-12 English
CRO Appointed to Conduct Phase 1b/2 Gastric Cancer Trial 2 pages 107.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the appointment of a Contract Research Organisation (CRO) to conduct a Phase 1b/2 clinical trial for a cancer drug. It discusses trial plans, timelines, and company background but does not contain financial data, regulatory filings, or detailed financial reports. It is an update on clinical trial progress and partnership, not a financial report, regulatory filing, or shareholder communication. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2015-06-30 English
Proposed Issue of Options to Dr Axel Hoos 1 page 60
Capital/Financing Update Classification · 95% confidence The document is an announcement from Imugene Limited regarding the proposed issue of options to a Non-Executive Director, Dr. Axel Hoos. It details the terms and conditions of the option issuance, including vesting conditions and exercise prices. There is no financial report, earnings data, or regulatory filing referenced beyond this announcement. The content focuses on a capital-related event involving share options granted to a director, which aligns with a capital or financing update. The document length is short (2457 characters), and it is not a report or a certification but a direct announcement of a capital-related decision. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-06-28 English
Prof Ursula Wiedermann Appointed Chief Scientific Officer 1
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Prof Ursula Wiedermann as Chief Scientific Officer of Imugene Limited. It focuses on management changes and does not contain financial data, regulatory filings, or report announcements. The content is about a senior management appointment, which fits the category of Board/Management Information (MANG). The document length is 3629 characters, which is relatively short and consistent with an announcement rather than a detailed report. There is no indication of financial results, voting results, or other report types.
2015-06-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.